Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma.

J Mark FitzGerald Eugene R Bleecker Arnaud Bourdin William Walter BusseGary T FergusonLaura BrooksPeter BarkerUbaldo J Martin

Published in: Journal of asthma and allergy (2019)

This benralizumab 2-year integrated analysis further supports long-term use of benralizumab for patients with severe, uncontrolled eosinophilic asthma.

Keyphrases

chronic obstructive pulmonary disease
lung function
early onset
cystic fibrosis
air pollution
drug induced